Biotech RadarJobs updated

COMPANY

Madrigal Pharmaceuticals

HQ: West Conshohocken, PA source · madrigalpharma.com ↗ · Mid-Atlantic

Clinical Phase 3

58 open jobs · last seen Oct 23, 2026 · 22 sources

Keywords: metabolic dysfunction-associated steatohepatitis liver disease metabolic MASH - Metabolic Dysfunction-Associated Steatohepatitis Liver Cirrhosis NASH - Nonalcoholic Steatohepatitis Non-Alcoholic Fatty Liver Disease Drug Safety Heart Failure With Preserved Ejection Fraction MASH NASH Heterozygous Familial Hypercholesterolemia Non-alcoholic Steatohepatitis Renal Impairment Hepatic Impairment Resmetirom MGL-3196 VIA-3196 MGL-3196 (resmetirom) Rezdiffra

Profile checked Oct 10, 2026

58+1 patient-care hiddenOpen jobs21Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Regional Sales Director - South Central2 locations, including Field, Houston TexasOct 21, 2026Oct 18, 2026
Director, Regulatory Affairs CMCPA - Conshohocken - OfficeOct 20, 2026Oct 21, 2026
Manager, BiostatisticsPA - Conshohocken - OfficeOct 16, 2026Oct 18, 2026
Senior Director, Data Operations & Enablement2 locations, including Office, Conshohocken, PAOct 16, 2026Oct 18, 2026
Associate Director, New Market Introduction and Life Cycle LeadZug - Switzerland - OfficeOct 16, 2026Oct 18, 2026

See all 58 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Board tracked Radar started tracking this company’s job board (59 open jobs at last check). source ↗
  2. Trial start Phase 4: Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis source ↗
  3. Trial start Phase 1: Resmetirom in Patients With MASH and HFpEF source ↗
  4. Trial start Phase 2: Study of Resmetirom in Children and Adolescents With MASH source ↗
  5. Trial start —: Rezdiffra Pregnancy and Lactation Registry source ↗
  6. Trial start Phase 2: Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH source ↗
  7. Trial start Phase 1: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control source ↗
  8. Trial start 3: A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) source ↗
  9. Trial start 3: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) source ↗
  10. Trial start 3: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients source ↗
  11. Trial start Phase 1: Drug Interaction Study of MGL-3196 With Clopidogrel source ↗
  12. Trial start 3: A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis source ↗
  13. Trial start Phase 1: Drug Interaction Study of MGL-3196 With Pioglitazone source ↗
  14. Trial start 1: Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjec source ↗
  15. Trial start Phase 1: Bioavailability Study of MGL-3196 Tablets Compared to Capsules source ↗
  16. Trial start Phase 1: Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196 source ↗
  17. Trial start Phase 2: Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) source ↗
  18. Trial start 2: Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) source ↗
  19. Trial start Phase 1: Drug Interaction Study of MGL-3196 With Atorvastatin source ↗
  20. Trial start Phase 1: Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin source ↗
  21. Trial start Phase 1: Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects source ↗
  22. Trial start Phase 1: Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 58

1 patient-care job hidden (phlebotomy, plasma-center, nursing and similar care roles; 59 open jobs in total).

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Regional Sales Director - South Central2 locations, including Field, Houston TexasOct 21, 2026Oct 18, 2026Not stated
Director, Regulatory Affairs CMCPA - Conshohocken - OfficeOct 20, 2026Oct 21, 2026Not stated
Manager, BiostatisticsPA - Conshohocken - OfficeOct 16, 2026Oct 18, 2026Not stated
Senior Director, Data Operations & Enablement2 locations, including Office, Conshohocken, PAOct 16, 2026Oct 18, 2026Not stated
Associate Director, New Market Introduction and Life Cycle LeadZug - Switzerland - OfficeOct 16, 2026Oct 18, 2026Not stated
Associate Director, Trial Master File Operations2 locations, including Office, Conshohocken, PAOct 15, 2026Oct 6, 2026Senior
Senior Manager, FP&A – G&A Business PartnerPA - Conshohocken - OfficeOct 15, 2026Oct 16, 2026Not stated
Vice President, Global Medical Lead - MASH2 locations, including Office, Conshohocken, PAOct 14, 2026Oct 15, 2026Executive
Associate Director, Sourcing Strategy & ProcurementZug - Switzerland - OfficeOct 13, 2026Oct 6, 2026Senior
Associate Director Drug Product SMEPA - Conshohocken - OfficeOct 13, 2026Oct 14, 2026Senior
Health Systems Regional Scientific DirectorChicago, Illinois - FieldOct 13, 2026Oct 14, 2026Senior
Health Systems Regional Scientific DirectorDenver, Colorado - FieldOct 13, 2026Oct 14, 2026Senior
Senior Manager, Brand Analytics & ForecastingPA - Conshohocken - OfficeOct 9, 2026Oct 5, 2026Senior
Health Systems Regional Scientific DirectorTX - Texas - FieldOct 7, 2026Oct 5, 2026Senior
Health Systems Regional Scientific DirectorPhiladelphia, Pennsylvania - FieldOct 7, 2026Oct 6, 2026Senior
Health Systems Regional Scientific DirectorMA - Massachusetts - FieldOct 7, 2026Oct 6, 2026Senior
Senior Director, Clinical Practice Liaison Team- East RegionPhiladelphia, Pennsylvania - FieldOct 7, 2026Oct 7, 2026Senior
Head of Market Access, ItalyMilano - Italy - OfficeOct 7, 2026Oct 8, 2026Executive
Senior Director, Global Safety PhysicianMA - Waltham - OfficeOct 6, 2026Oct 6, 2026Senior
Director, Drug Product SMEPA - Conshohocken - OfficeOct 6, 2026Oct 6, 2026Senior
Associate Director, Global Scientific Content2 locations, including Office, Conshohocken, PAOct 2, 2026Oct 5, 2026Senior
Director, Field Execution and ExcellenceRemote - USOct 1, 2026Oct 5, 2026Senior
Key Account Director - SouthwestOK - Oklahoma - FieldSep 30, 2026Oct 5, 2026Senior
Key Account Director - HeartlandMO - Missouri - FieldSep 30, 2026Oct 5, 2026Senior
VP, Scientific IT Business PartnerPA - Conshohocken - OfficeSep 28, 2026Oct 5, 2026Executive
Associate Director, U.S. Tax Operations & ReportingMA - Waltham - OfficeSep 28, 2026Oct 5, 2026Senior
Senior BiostatisticianPA - Conshohocken - OfficeSep 25, 2026Oct 5, 2026Senior
Clinical Practice Liaison - South Florida/Puerto RicoMiami, FLSep 23, 2026Oct 5, 2026Mid
Senior Director, Regulatory Affairs CMC2 locations, including Office, Waltham, MASep 23, 2026Oct 5, 2026Senior
Executive Director, U.S. HCP Marketing2 locations, including Office, Conshohocken, PASep 23, 2026Oct 5, 2026Executive
Senior Director, Participant Recruitment and RetentionPA - Conshohocken - OfficeSep 23, 2026Oct 5, 2026Senior
Executive Director, Operations Lead2 locations, including Office, Conshohocken, PASep 23, 2026Oct 5, 2026Executive
Director, API External Manufacturing LeadZug - Switzerland - OfficeSep 23, 2026Oct 5, 2026Senior
Senior Medical Director, Early Clinical Development & Translational Medicine (MD)2 locations, including Office, Conshohocken, PASep 23, 2026Oct 5, 2026Senior
Associate Director, Development Quality – OSD2 locations, including Office, Conshohocken, PASep 23, 2026Oct 5, 2026Senior
Vice President, Clinical Development Program LeaderPA - Conshohocken - OfficeSep 23, 2026Oct 5, 2026Executive
Associate Director, MSAT APIZug - Switzerland - OfficeSep 23, 2026Oct 5, 2026Senior
Senior Director, Clinical Operations2 locations, including Office, Conshohocken, PASep 23, 2026Oct 5, 2026Senior
Director, Quality – New Product Development LeadPA - Conshohocken - OfficeSep 23, 2026Oct 5, 2026Senior
Senior Manager, MSAT Product Knowledge StewardPA - Conshohocken - OfficeSep 23, 2026Oct 5, 2026Senior
Senior Director, BioanalysisPA - Conshohocken - OfficeSep 23, 2026Oct 5, 2026Senior
Director, Clinical PharmacologyPA - Conshohocken - OfficeSep 23, 2026Oct 5, 2026Senior
Thought Leader Liaison- Cleveland/PittsburghOH - Ohio - FieldSep 23, 2026Oct 5, 2026Senior
Director, Market Access InternationalZug - Switzerland - OfficeSep 23, 2026Oct 5, 2026Senior
Associate Director, Manufacturing Technical Project Management (MSAT)PA - Conshohocken - OfficeSep 23, 2026Oct 5, 2026Senior
Senior Director, Clinical Supply ReleaseRemote - USSep 23, 2026Oct 5, 2026Senior
Thought Leader Liaison - Great LakesMI - Michigan - FieldSep 23, 2026Oct 5, 2026Senior
Access Reimbursement Manager - Puerto RicoPR - Puerto Rico - FieldSep 23, 2026Oct 5, 2026Mid
Senior Manager, GCP Quality AssurancePA - Pennsylvania – RemoteSep 23, 2026Oct 5, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 58 jobs →

Clinical trials (lead sponsor) 21

RecordTitlePhaseStatusStartPrimary completion
NCT07848191Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisPhase 4Not yet recruiting2026-092027-11 (estimated)
NCT07830758Resmetirom in Patients With MASH and HFpEFPhase 1Not yet recruiting2026-092027-11 (estimated)
NCT07763015Study of Resmetirom in Children and Adolescents With MASHPhase 2RecruitingAug 1, 20262029-07 (estimated)
NCT07335601Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHPhase 2RecruitingDec 29, 20252028-08 (estimated)
NCT05500222A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)3Active, not recruitingAug 26, 20222026-12 (estimated)
NCT03038022Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)Phase 2CompletedFeb 23, 2017Jan 15, 2018 (actual)
NCT03900429A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis3Active, not recruitingMar 28, 20192028-01 (estimated)
NCT04951219A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)3Active, not recruitingJul 9, 20212027-03 (estimated)
NCT07541469Rezdiffra Pregnancy and Lactation RegistryNot listedRecruitingMar 4, 2026Apr 8, 2030 (estimated)
NCT02912260Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)2CompletedOct 18, 2016Oct 25, 2017 (actual)
NCT06397872A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal FunctionPhase 1CompletedMar 6, 2024Sep 16, 2024 (actual)
NCT04643795Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects1CompletedOct 25, 2018Aug 4, 2021 (actual)
NCT04197479A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients3CompletedDec 16, 2019Jan 6, 2023 (actual)
NCT01367873Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy SubjectsPhase 1Completed2011-062011-10 (actual)
NCT02542969Drug Interaction Study of MGL-3196 With Rosuvastatin and SimvastatinPhase 1Completed2015-092015-10 (actual)
NCT04671069Drug Interaction Study of MGL-3196 With ClopidogrelPhase 1CompletedJul 26, 2019Aug 30, 2019 (actual)
NCT04671056Drug Interaction Study of MGL-3196 With PioglitazonePhase 1CompletedNov 9, 2018Dec 11, 2018 (actual)
NCT03413124Bioavailability Study of MGL-3196 Tablets Compared to CapsulesPhase 1CompletedFeb 5, 2018Feb 17, 2018 (actual)
NCT03220165Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196Phase 1CompletedAug 6, 2017Sep 3, 2017 (actual)
NCT02749578Drug Interaction Study of MGL-3196 With AtorvastatinPhase 1Completed2016-042016-05 (actual)
NCT01519531Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy SubjectsPhase 1Completed2012-012012-11 (actual)

Connect

See your connections at Madrigal Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback